

## Special Issue

# Immunogenic Effects of Electroporation-Based Treatments

### Message from the Guest Editors

Studies in the field of immunology are revealing an attractive set of novel and different therapeutic approaches to treat cancer and infectious diseases. Electroporation, also named electroporomeabilization (EP), is an efficient and safe technique based on the application of voltage pulses of sufficient strength and duration to generate transient membrane permeabilization/poration, thus allowing the delivery of drugs or genetic material into the target cells via electrotransfer. Following EP treatments, different innate and adaptive immune cells can be recruited, influencing immune responses at local and distant levels. Due to this property, many studies in the field of immunization by electroporation have been undertaken. In this Special Issue, induction of immunological effects and enhancement of the immune system response induced by genetic vaccines and/or immunomodulatory molecules, administered alone or in combination with other therapeutic treatments by EP, will be discussed. Presentations of results on the immunological effects of drugs delivered by electric fields in pre-clinical and clinical trials will be very welcome as well.

### Guest Editors

Prof. Dr. Emanuela Signori

Prof. Dr. Maja Čemažar

Prof. Mariangela De Robertis

Prof. Loreé C. Heller

Prof. Dr. Richard Heller

### Deadline for manuscript submissions

closed (31 March 2023)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/78407](https://mdpi.com/si/78407)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).